Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

NEUROTROPHIC EFFECTS OF ETIFOXINE

https://doi.org/10.14412/2074-2711-2016-4-65-70

Abstract

Higher anxiety results in the decreased levels of various neurotrophic factors and enkephalins and in impaired production of proinflammatory cytokines. The anxiolytic etifoxine is used to treat anxiety states and adjustment disorders. Etifoxine modulates the GABAergic transmission and metabolism of neurosteroids. The latter determines the unique neurotrophic and neuroprotective properties of the drug, such as increased expression of neurotrophic factors, regeneration of nerve fibers, and preservation and regeneration of myelin sheaths. Other important pharmacological effects of an etifoxine molecule have been also discovered; these are to relieve allodynia related to 3α-steroids and GABA receptors and to effectively treat cerebral edema, experimental autoimmune encephalitis, and excessive nervous excitability in the presence of alcohol withdrawal. In addition, the chemoreactome simulation of the molecule of etifoxine has established that its attenuated side effects are due to its lower interaction with serotonin, acetylcholine, adrenergic and other neurotransmitter receptors than is shown by benzodiazepines. Etifoxine has been also found to have anti-inflammatory (due to antihistamine and antileukotriene effects) and antitumor activities and an ability to affect hemodynamics and vessel walls.

The paper presents a systematic analysis of the results of trials of the neurotrophic properties of etifoxine. It considers how the drug stimulates the expression of neurotrophic factors, accelerates the maturation and regeneration of nerve fibers, and regenerates myelin sheaths.

The neurotrophic effects of etifoxine along with its anxiolytic activity will accelerate the recovery of patients with different neurological diseases and enhance the quality of their neurorehabilitation.

About the Authors

I. Yu. Torshin
Moscow Institute of Physics and Technology
Russian Federation

9, Institutsky Lane, Dolgoprudnyi, Moscow Region 141700



O. A. Gromova
Ivanovo State Medical Academy; Neurobiology Russian Satellite Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Medical Research University
Russian Federation

8, Sheremetevsky Passage, Ivanovo 153000; 1, Ostrovityanov St., Moscow 117997



V. A. Semenov
Kemerovo State Medical Academy
Russian Federation

22A, Voroshilov St., Kemerovo 650056



O. A. Limanova
Ivanovo State Medical Academy; Neurobiology Russian Satellite Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Medical Research University
Russian Federation

8, Sheremetevsky Passage, Ivanovo 153000; 1, Ostrovityanov St., Moscow 117997



I. V. Gogoleva
Ivanovo State Medical Academy; Neurobiology Russian Satellite Center, Trace Element Institute for UNESCO, N.I. Pirogov Russian National Medical Research University
Russian Federation

8, Sheremetevsky Passage, Ivanovo 153000; 1, Ostrovityanov St., Moscow 117997



References

1. Stein D. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2015 Jan;32(1):57-68. doi: 10.1007/s12325-015-0176-6. Epub 2015 Jan 27.

2. Bouillot C, Bonnefoi F, Liger F, Zimmer L. A microPET comparison of the effects of etifoxine and diazepam on [(11)C]flumazenil uptake in rat brains. Neurosci Lett. 2016 Jan 26;612:74-9. doi: 10.1016/j.neulet.2015.11.042. Epub 2015 Nov 28.

3. do Rego J, Vaudry D, Vaudry H. The nonbenzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One. 2015 Mar 18;10(3):e0120473. doi: 10.1371/journal.pone.0120473.eCollection 2015.

4. Торшин ИЮ, Громова ОА, Федотова ЛЭ, Громов АН. Систематический анализ фундаментальных и клинических исследований этифоксина. Неврология, нейропсихиатрия, психосоматика. 2016;8(3):106-12. [Torshin IYu, Gromova OA, Fedotova LE, Gromov AN. Systematic analysis of basic and clinical studies of etifoxine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):106-12. (In Russ.)]. DOI:10.14412/2074-2711-2016-3-106-112

5. Zeitler A, Kamoun N, Goyon S, et al. Favouring inhibitory synaptic drive mediated by GABAA receptors in the basolateral nucleus of the amygdala efficiently reduces pain symptoms in neuropathic mice. Eur J Neurosci. 2016 Apr;43(8):1082-8. doi: 10.1111/ejn.13217. Epub 2016 Mar 17.

6. Girard P, Pansart Y, Gillardin JM. Preventive and curative effects of etifoxine in a rat model of brain oedema. Clin Exp Pharmacol Physiol. 2009 Jul;36(7):655-61. doi: 10.1111/j.1440-1681.2008.05127.x. Epub 2009 Nov 28.

7. Ravikumar B, Crawford D, Dellovade T, et al. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of Multiple Sclerosis. Neuropharmacology. 2016 Sep;108:229-37. doi: 10.1016/j.neuropharm.2016.03.053. Epub 2016 Mar 30.

8. Verleye M, Heulard I, Gillardin J. The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice. Alcohol. 2009 May;43(3):197-206. doi: 10.1016/j.alcohol.2009.02.003.

9. Торшин ИЮ, Громова ОА, Фетотова ЛЭ, Громов АН. Эффекты этифоксина (хемореактомное моделирование). Неврология, нейропсихиатрия, психосоматика. 2016;8(2):44-49. [Torshin IYu, Gromova OA, Fedotova LE, Gromov AN. Effects of etifoxine: Chemoreactome simulation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2016;8(2): 44–49. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2016-2-44-49

10. Dai T, Zhou X, Li Y, et al. Etifoxine promotes glia-derived neurite outgrowth in vitro and in vivo. J Reconstr Microsurg. 2014 Jul;30(6):381-8. doi: 10.1055/s-0034-1381751. Epub 2014 Jun 23.

11. Wolf L, Bauer A, Melchner D, et al. Enhancing neurosteroid synthesis – relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry. 2015 Mar;48(2): 72-7. doi: 10.1055/s-0034-1398507. Epub 2015 Feb 5.

12. Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav. 2005 Dec;82(4):712-20. Epub 2006 Jan 4.

13. Schumacher M, Guennoun R, Mercier G, et al. Progesterone synthesis and myelin formation in peripheral nerves. Brain Res Brain Res Rev. 2001 Nov;37(1-3):343-59.

14. Zhou X, He X, He B, et al. Etifoxine promotes glialderived neurotrophic factorinduced neurite outgrowth in PC12 cells. Mol Med Rep. 2013 Jul;8(1):75-80. doi: 10.3892/mmr.2013.1474. Epub 2013 May 13.

15. Girard C, Liu S, Adams D, et al. Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. J Neuroendocrinol. 2012 Jan;24(1):71-81. doi: 10.1111/j.1365-2826.2011.02215.x.

16. Girard C, Liu S, Cadepond F, et al. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Natl Acad Sci USA. 2008 Dec 23;105(51):20505-10. doi: 10.1073/ pnas.0811201106. Epub 2008 Dec 15.

17. Zhou X, He B, Zhu Z, et al. Etifoxine provides benefits in nerve repair with acellular nerve grafts. Muscle Nerve. 2014 Aug;50(2): 235-43. doi: 10.1002/mus.24131. Epub 2014 May 15.

18. Daugherty D, Selvaraj V, Chechneva O, et al. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med. 2013 Jun;5(6):891-903. doi: 10.1002/emmm.201202124. Epub 2013 May 17.

19. Крыжановский ГН, Магаева СВ, Макаров СВ, Сепиашвили РИ; Черешнев ВА, редактор. Нейроиммунопатология: руководство. Москва: Издательство НИИ общей патологии и патофизиологии; 2005. 438 с. [Kryzhanovskii GN, Magaeva SV, Makarov SV, Sepiashvili RI; Chereshnev VA, editor. Neiroimmunopatologiya: rukovodstvo [Neuroimmunopathology: guide]. Moscow: Izdatel'stvo NII obshchei patologii i patofiziologii; 2005. 438 p.].


Review

Views: 1872


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)